Targeting Novel BMPR2 modifiers in Pulmonary Hypertension with Repurposed Drugs
Targeting Novel BMPR2 modifiers in Pulmonary Hypertension with Repurposed Drugs
批准号:
9923720
负责人:
Edda Frauke Spiekerkoetter
金额:
$43.65万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-05-01 至 2021-04-30
关键词:
AdenovirusesAdoptionAnimal ModelApoptosisBiological AssayBlood VesselsCell ProliferationCellsCessation of lifeChemosensitizationClinicClinicalDNA DamageDasatinibDataData SetDatabasesDevelopmentDiseaseDoseEndotheliumEnhancersEpigenetic ProcessFDA approvedFHIT geneFK506FaceFibroblastsGene ExpressionGenesGenetic TranscriptionGoalsHeart failureHistopathologyHumanHypoxiaImmuneImpairmentLeftLinkLungLung TransplantationLymphocyte-Specific p56LCK Tyrosine Protein KinaseMessenger RNAMeta-AnalysisMicroRNAsMissionModelingNational Heart, Lung, and Blood InstituteNude RatsPathogenesisPathologyPathway interactionsPatientsPenetrancePharmaceutical PreparationsPharmacologyPhase II Clinical TrialsPhenotypeProliferatingPulmonary HypertensionPulmonary Vascular ResistancePulmonary artery structureRattusRegulationResearchRodentSafetySignal TransductionSmall Interfering RNASmooth Muscle MyocytesSpeedStructure of parenchyma of lungTherapeuticTimeToxic effectTranslatingTranslationsTubeVascular DiseasesVasodilator AgentsWorkbasebone morphogenetic protein receptorscell typeclinical practicecosthigh riskhigh throughput screeningimprovedinnovationmRNA Expressionnew therapeutic targetnovelnovel therapeuticsoverexpressionpreventpublic health relevancepulmonary arterial hypertensionpulmonary artery endothelial cellpulmonary functionreceptortranscription factortranscriptomics
中文摘要
描述(申请人提供:我们目前主要使用血管扩张剂治疗肺动脉高压(PAH),与逆转导致肺血管阻力增加和右心衰竭的肺动脉闭塞性血管病变的需要之间存在根本差距。骨形态发生蛋白受体2(BMPR2)信号被认为是PAH的关键途径和潜在的主开关,BMPR2表达降低与血管细胞增殖和闭塞性血管病变有关。因此,这项建议的总体目标是开发新的治疗方法,通过增加BMPR2表达的新途径来逆转闭塞性血管病变。PAH患者BMPR2下调的机制尚不清楚。增加BMPR2信号的策略在实验性肺动脉高压中显示出希望,但大多数方法在临床应用之前仍面临许多障碍。因此,识别BMPR2修饰基因,可以利用改变用途的药物来增加BMPR2的表达,将是一个有希望的策略,以改善PAH具有明确的治疗转译途径。我们的建议有三个重要的部分,具体表现为我们的三个具体目标:第一,我们将专注于新的BMPR2修饰基因,脆性组氨酸三联体(FHIT)和淋巴细胞特异性蛋白酪氨酸激酶(LCK),我们在siRNA高通量筛选(HTS)中发现了这些基因,它们不仅在PAH中具有重要的功能,而且在PAH转录数据库的荟萃分析中也高度表达。我们的初步数据表明,FHIT和LCK的表达减少导致BMPR2mRNA的表达减少,肺血管细胞功能受损。我们对人PAH肺组织、内皮细胞和免疫细胞的研究表明,FHIT和LCK在PAH中表达下调,并改变了家族性PAH的疾病外显性。其次,我们将使用候选的和无偏见的分析方法来确定FHIT和LCK如何在表观遗传和转录水平上调节BMPR2。第三,我们将确定一种增加FHIT的药物enzastaurin是否可以逆转人类血管细胞的异常表型和实验性肺动脉高压,从而为治疗转化提供一条明确的途径。我们的方法有三个创新方面:(1)在概念上,我们将通过调控两个以前在PAH中尚未描述的新基因来靶向BMPR2的表达;(2)在技术上,我们使用了一种尚未被用于鉴定PAH中的BMPR2修饰基因的新型siRNA高通量筛选;(3)在药理学上,我们将重新调整现有药物的用途,这些药物不仅节省时间和费用,而且由于监管机构已知的安全性和毒性信息,可以加快它们在临床上的采用。我们提出的研究对PAH领域的贡献非常重要,因为它利用新的途径通过重新定位先前与受体或PAH无关的药物来调节BMPR2基因的表达。
英文摘要
DESCRIPTION (provided by applicant: There is a fundamental gap between our current treatment for Pulmonary Arterial Hypertension (PAH) with primarily vasodilators, and the need to reverse the occlusive vasculopathy of pulmonary arteries that results in increased pulmonary vascular resistance and right heart failure. Increasingly, Bone Morphogenetic Protein Receptor 2 (BMPR2) signaling is recognized as a key pathway and potential master switch in PAH with reduced BMPR2 expression implicated in vascular cell proliferation and occlusive vasculopathy. The overall goal of this proposal thus is to develop new therapies to reverse the occlusive vasculopathy by novel pathways that increase BMPR2 expression. The mechanism by which BMPR2 is downregulated in PAH patients is not known. Strategies to increase BMPR2 signaling have shown promise in experimental pulmonary hypertension yet most approaches still face many obstacles before they can be used clinically. Thus, identifying BMPR2 modifier genes that could be harnessed with repurposed drugs to increase BMPR2 expression would be a promising strategy to improve PAH with a clear path to therapeutic translation. Our proposal has three significant parts, which are represented by our three specific aims: First, we will focus on novel BMPR2 modifier genes, Fragile Histidine Triad (FHIT) and Lymphocyte specific protein tyrosine Kinase (LCK) that we identified in an siRNA High Throughput Screen (HTS) and that are not only functionally important in PAH but also highly represented in a meta-analysis of PAH transcriptomic databases. Our strong preliminary data showed that decreased expression of FHIT and LCK resulted in reduced BMPR2 mRNA expression and impaired function of pulmonary vascular cells. Our studies on human PAH lung tissue, endothelial as well as immune cells suggested that FHIT and LCK are downregulated in PAH and modify disease penetrance in familial PAH. Second, we will determine how FHIT and LCK regulate BMPR2 on the epigenetic and transcriptional level using candidate and unbiased profiling assay approaches. Third, we will determine whether a drug that increases FHIT, Enzastaurin, reverses the abnormal phenotype of human vascular cells and experimental pulmonary hypertension, thus offering a clear path to a therapeutic translation. Three innovative aspects underlie our approach: (1) conceptually, we will target BMPR2 expression by modulating two novel genes that have not been describe in PAH before (2) technically, we used a novel siRNA high Throughput Screen that has not been used to identify BMPR2 modifier genes in PAH and (3) pharmacologically, we will repurpose existing drugs which not only saves time and expense but can speed their adoption in the clinic because of known safety and toxicity information from regulatory agencies. The contribution of our proposed research is highly significant to the field o PAH, as it utilizes novel pathways to regulate BMPR2 gene expression by repurposing drugs not previously linked to either the receptor or to PAH.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Understanding and targeting molecular and cellular events responsible for pulmonary arteriovenous malformation development, growth and regression
-
批准号:10718086
-
项目类别:
-
资助金额:$69.62万
-
财政年份:2023
-
负责人:Edda Frauke Spiekerkoetter
-
依托单位:
Understanding and targeting molecular as well as structural events governing right ventricular adaptation, failure and recovery in pulmonary hypertension using repurposed drugs
-
批准号:10615148
-
项目类别:
-
资助金额:$41.84万
-
财政年份:2021
-
负责人:Edda Frauke Spiekerkoetter
-
依托单位:
Understanding and targeting molecular as well as structural events governing right ventricular adaptation, failure and recovery in pulmonary hypertension using repurposed drugs
-
批准号:10456651
-
项目类别:
-
资助金额:$41.18万
-
财政年份:2021
-
负责人:Edda Frauke Spiekerkoetter
-
依托单位:
Understanding and targeting molecular as well as structural events governing right ventricular adaptation, failure and recovery in pulmonary hypertension using repurposed drugs
-
批准号:10278668
-
项目类别:
-
资助金额:$41.93万
-
财政年份:2021
-
负责人:Edda Frauke Spiekerkoetter
-
依托单位:
Modulating BMPRII Signaling in Pulmonary Arterial Hypertension
-
批准号:8890864
-
项目类别:
-
资助金额:$12.12万
-
财政年份:2011
-
负责人:Edda Frauke Spiekerkoetter
-
依托单位:
Modulating BMPRII Signaling in Pulmonary Arterial Hypertension
-
批准号:8308378
-
项目类别:
-
资助金额:$12.12万
-
财政年份:2011
-
负责人:Edda Frauke Spiekerkoetter
-
依托单位:
Modulating BMPRII Signaling in Pulmonary Arterial Hypertension
-
批准号:8520385
-
项目类别:
-
资助金额:$12.12万
-
财政年份:2011
-
负责人:Edda Frauke Spiekerkoetter
-
依托单位:
Modulating BMPRII Signaling in Pulmonary Arterial Hypertension
-
批准号:8703752
-
项目类别:
-
资助金额:$12.12万
-
财政年份:2011
-
负责人:Edda Frauke Spiekerkoetter
-
依托单位:
Modulating BMPRII Signaling in Pulmonary Arterial Hypertension
-
批准号:8091016
-
项目类别:
-
资助金额:$12.12万
-
财政年份:2011
-
负责人:Edda Frauke Spiekerkoetter
-
依托单位:
海外基金